Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.

Esin Aysel Kandemir İrem Karaçömerlioğlu Ibrahim Muaz Yaradilmis

Published in: Journal of cancer research and clinical oncology (2023)

Off-label use of ICIs was primarily related to (NSCLC), and most patients were treatment-naïve in contrast to the acceptance that off-label use results from exhausted treatment options. Lack of approval is a significant reason for the off-label use of ICIs.

Keyphrases

end stage renal disease
chronic kidney disease
small cell lung cancer
ejection fraction
peritoneal dialysis
computed tomography
newly diagnosed
combination therapy
replacement therapy